ATLAS / Macro Radar / Reporting / IMRX

Immuneering Corp (IMRX) reporting calendar

Immuneering Corp files periodic reports with the SEC as IMRX on Nasdaq. Atlas tracks 20 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
22 Jul 2026 – 4 Sep 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
15 May 2026
Reports on record
20

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 44 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Open IMRX market profile Latest filing on SEC EDGAR ↗ Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202615 May 202645 days0001790340-26-000057
10-K31 Dec 20256 Mar 202665 days0001790340-26-000042
10-Q30 Sep 202512 Nov 202543 days0001790340-25-000135
10-Q30 Jun 202513 Aug 202544 days0001790340-25-000104
10-Q31 Mar 20255 May 202535 days0001790340-25-000061
10-K31 Dec 202420 Mar 202579 days0001790340-25-000042
10-Q30 Sep 202413 Nov 202444 days0001790340-24-000080
10-Q30 Jun 20246 Aug 202437 days0001790340-24-000066
10-Q31 Mar 20247 May 202437 days0001790340-24-000056
10-K31 Dec 20231 Mar 202461 days0001790340-24-000024
10-Q30 Sep 20239 Nov 202340 days0001790340-23-000056
10-Q30 Jun 20233 Aug 202334 days0001790340-23-000048
10-Q31 Mar 20234 May 202334 days0001790340-23-000023
10-K31 Dec 20226 Mar 202365 days0001558370-23-002905
10-Q30 Sep 202210 Nov 202241 days0001558370-22-017304
10-Q30 Jun 202210 Aug 202241 days0001558370-22-013063
10-Q31 Mar 202210 May 202240 days0001558370-22-007953
10-K31 Dec 202110 Mar 202269 days0001558370-22-003208
10-Q30 Sep 20219 Nov 202140 days0001558370-21-015147
10-Q30 Jun 20219 Sep 202171 days0001558370-21-012336

Source: SEC EDGAR company submissions for CIK 0001790340. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.